Loading data for RNXT — first visit, this takes a few seconds.
RenovoRx, Inc. (RNXT)
NasdaqCM: RNXT
· Real-Time Price · USD
1.93
+0.26 (15.57%)
At close: Aug 31, 2026, 3:59 PM
1.98
+2.56%
After-hours: 7:59 PM
The price, the headline numbers and the latest news, in one place.
RenovoRx, Inc. (RNXT) Stock Price, Analysis & Data
15.57% (1D)
| Bid | 1.87 |
| Market Cap | 87.1M |
| Revenue (ttm) | 1.98M |
| Net Income (ttm) | -12.3M |
| 0.99 | |
| -0.31 | |
| n/a | |
| -16.08 | |
| P/B (ttm) | 9.70 |
| P/S (ttm) | 44.08 |
| Earnings Date | Aug 14, 2025 |
| Ask | 1.89 |
| Volume | 3,269,585 |
| Avg. Volume (20D) | 357,874 |
| Open | 1.72 |
| Previous Close | 1.67 |
| Day's Range | 1.65 - 1.97 |
| 52-Week Range | 0.70 - 1.97 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, Calif...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2021
Employees 17
Stock Exchange NasdaqCM
Ticker Symbol RNXT
Website https://renovorx.com
Financial Performance
In 2025, RenovoRx's revenue was 1.12M, an increase of 2,511.63% compared to the previous year's 43K. Earnings were -11.17M, an increase of 26.71%.
Financial StatementsEarnings Surprise
RenovoRx has released their quarterly earnings on Aug 12, 2026:
- Revenue of $563K misses estimates by $0, with 185.79% YoY growth.
- EPS of -0.05 exceeds estimates by 0.02, with 37.50% YoY growth.
RenovoRx, Inc. is scheduled to release its earnings on Aug 14, 2025, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2